Efficacy and safety of alogliptin added to pioglitazone in Japanese patients with type 2 diabetes: a randomized, double‐blind, placebo‐controlled trial with an open‐label long‐term extension study
The DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.
Abstract
Aim: To assess the efficacy and safety of alogliptin added to pioglitazone versus pioglitazone monotherapy, in Japanese patients with type 2 diabetes who achieved inadequate glycaemic control on pioglitazone plus diet/exercise. Methods: Patients were stabilized on pioglitazone 15 or 30 mg/day plus diet/exercise during a 16‐week screening period. Patients with HbA1c of 6.9–10.4% were randomized to 12 weeks' double‐blind treatment with alogliptin 12.5 or 25 mg once daily or placebo, added to their stable pioglitazone regimen. The primary endpoint was the change in HbA1c from baseline to week 12. Patients had an option to continue in a 40‐week, open‐label extension study, with those originally randomized to alogliptin remaining on the same dosage regimen while patients treated with placebo were randomly allocated to alogliptin 12.5 or 25 mg (added to their stable pioglitazone). Results: The change from baseline in HbA1c after 12 weeks was significantly greater with alogliptin 12.5 mg added to pioglitazone and alogliptin 25 mg added to pioglitazone than with placebo added to pioglitazone (−0.91 and −0.97% vs. −0.19%; p < 0.0001). Responder rates (HbA1c <6.9% and HbA1c <6.2%) and changes in fasting and postprandial blood glucose levels showed a similar positive trend in terms of glycaemic control. The benefits seen with alogliptin were sustained during the 40‐week extension period. Alogliptin added to pioglitazone was generally well tolerated; hypoglycaemia was infrequent and increases in body weight were minor. Conclusions: Once‐daily alogliptin was effective and generally well tolerated when given as add‐on therapy to pioglitazone in Japanese patients with type 2 diabetes who achieved inadequate glycaemic control on pioglitazone plus lifestyle measures. Clinical benefits were maintained for 52 weeks.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Nathan, D. M., Buse, J. B., Davidson, M. B., Ferrannini, E., Holman, R. R., Sherwin, R., & Zinman, B. (2009) · Diabetes Care · doi:10.2337/dc08-9025 · Cited by 3,834
Turner, R. C. (1999) · JAMA · doi:10.1001/jama.281.21.2005 · Cited by 2,375 · cited 2×
“Consequently, there is often a need for combination therapy, using drugs with different mechanisms of action [2,5].”
BackgroundNauck, M. A., Heimesaat, M. M., Orskov, C., Holst, J. J., Ebert, R., & Creutzfeldt, W. (1993) · Journal of Clinical Investigation · doi:10.1172/jci116186 · Cited by 1,651
Seino, Y., Nanjo, K., Tajima, N., Kadowaki, T., Kashiwagi, A., Araki, E., Ito, C., Inagaki, N., Iwamoto, Y., Kasuga, M., et al. (2010) · Diabetology International · doi:10.1007/s13340-010-0006-7 · Cited by 614
Self-citationSecretion of glucagon-like peptide-1 (GLP-1) in type 2 diabetes: what is up, what is down?
Nauck, M. A., Vardarli, I., Deacon, C. F., Holst, J. J., & Meier, J. J. (2011) · Diabetologia · doi:10.1007/s00125-010-1896-4 · Cited by 465
Cited by
Update on the treatment of type 2 diabetes mellitus
Marín-Peñalver, J. J., Martín-Timón, I., Sevillano-Collantes, C., & Cañizo-Gómez, F. J. D. (2016) · World Journal of Diabetes · doi:10.4239/wjd.v7.i17.354 · Cited by 647
Qaseem, A., Humphrey, L. L., Sweet, D. E., Starkey, M., Shekelle, P., & for the Clinical Guidelines Committee of the American College of Physicians* (2012) · Annals of Internal Medicine · doi:10.7326/0003-4819-156-3-201202070-00011 · Cited by 400
Kim, Y. G., Hahn, S., Oh, T. J., Kwak, S. H., Park, K. S., & Cho, Y. M. (2013) · Diabetologia · doi:10.1007/s00125-012-2827-3 · Cited by 396
Li, L., Shen, J., Bala, M. M., Busse, J. W., Ebrahim, S., Vandvik, P. O., Rios, L. P., Malaga, G., Wong, E., Sohani, Z., et al. (2014) · BMJ · doi:10.1136/bmj.g2366 · Cited by 254
Dipeptidyl peptidase-4 inhibitors in type 2 diabetes therapy – focus on alogliptin
Giugliano, D., Sportiello, L., Capuano, A., Maiorino, M., Rossi, F., & Esposito, K. (2013) · Drug Design, Development and Therapy · doi:10.2147/dddt.s37647 · Cited by 86
Metadata
- Authors
- Kaku, K., Itayasu, T., Hiroi, S., Hirayama, M., & Seino, Y.
- Venue
- Diabetes, Obesity and Metabolism
- Publisher
- Wiley
- Published
- 2011-09-28
- Volume
- 13
- Issue
- 11
- Pages
- 1028-1035
- ISSN
- 1462-8902 (ISSN-L)
- 1463-1326
- OpenAlex
- W2092918268
- Cited by
- 85
- References
- 5
- FWCI
- 8.47
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Efficacy and safety of alogliptin added to pioglitazone in Japanese patients with type 2 diabetes: a randomized, double‐blind, placebo‐controlled trial with an open‐label long‐term extension study. https://app.cochat.ai/papers/10.1111/j.1463-1326.2011.01460.x
- The paper
- Kaku, K., Itayasu, T., Hiroi, S., Hirayama, M., & Seino, Y. (2011). Efficacy and safety of alogliptin added to pioglitazone in Japanese patients with type 2 diabetes: a randomized, double‐blind, placebo‐controlled trial with an open‐label long‐term extension study. Diabetes, Obesity and Metabolism. https://doi.org/10.1111/j.1463-1326.2011.01460.x
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.